Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07674966 · ClinicalTrials.gov registry record · Phase 1
An Investigation of Topical Ophthalmic Low-Dose Atropine on Pupil Size and Accommodation
A Phase 1 study, sponsored by University of California, Berkeley.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07674966: Completed Phase 1 study, sponsored by University of California, Berkeley.
NCT07674966 is a Phase 1 study that has completed, run by University of California, Berkeley. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07674966, a Phase 1 study, has completed, sponsored by University of California, Berkeley.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The goal of this clinical study is to learn about the short-term physiological effects of low-dose atropine in healthy volunteers. The study seeks to examine three questions related to low-dose topically applied ophthalmic atropine: 1. Does applying two drops of 0.01% atropine sulfate solution cause the same clinical effects as one drop of 0.02% atropine? 2. How quickly do the pupil responses and accommodative amplitudes recover following a dose of 0.01% atropine, 0.02% atropine, and 0.05% atropine? 3. Does applying a single drop of 0.02% atropine sulfate solution cause the same clinical effects in participants with light vs. dark iris colors? Participants will have their pupil size and accommodative status measured at appropriate intervals to answer the questions above.
Primary Outcome
Dynamic pupil responses to a single pulse of light were measured 1 hour, 2 hours, 4 hours, 8 hours, and 24 hours after instilling the drop(s). The smallest pupil size (maximum pupil restriction) was used as the primary outcome measure.
Interventions
- DRUG Atropine 0.01% Ophthalmic Solution
- DRUG Atropine 0.02% Ophthalmic Solution
- DRUG Atropine 0.05% Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-03-16 |
| Est. Completion | 2022-10-09 |
| Phase | Phase 1 |
What the finished NCT07674966 record still lists
NCT07674966 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 3 interventions - of which Atropine 0.01% Ophthalmic Solution is the first listed.
NCT07674966 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07674966 about?
NCT07674966 is a clinical study titled "An Investigation of Topical Ophthalmic Low-Dose Atropine on Pupil Size and Accommodation". The goal of this clinical study is to learn about the short-term physiological effects of low-dose atropine in healthy volunteers. The study seeks to examine three questions related to low-dose topically applied ophthalmic atropine: 1. Does applying two drops of 0.01% atropine sulfate solution caus...
What is the current status of trial NCT07674966?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-03-16. Estimated completion is 2022-10-09.
What interventions are being tested in trial NCT07674966?
The interventions under investigation include: Atropine 0.01% Ophthalmic Solution (DRUG), Atropine 0.02% Ophthalmic Solution (DRUG), Atropine 0.05% Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT07674966?
This trial is sponsored by University of California, Berkeley, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07674966's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI